Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

Benzinga · 6d ago
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.